STOCK TITAN

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) to present at the TD Cowen 44th Annual Healthcare Conference in March 2024. Dave Lennon, President and CEO, to provide a company overview on precision therapies for patients with mTOR pathway alterations.
Positive
  • None.
Negative
  • None.

LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston. Dave Lennon, Ph.D., President and CEO, will present a company overview on Monday, March 4, 2024, from 2:10 PM – 2:40 PM ET.

The presentation will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for cancers to bring transformational therapies to cancer patients with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. Aadi received FDA approval and has commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
IR@aadibio.com

(PRNewsfoto/Aadi Bioscience)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-at-the-td-cowen-44th-annual-healthcare-conference-302071520.html

SOURCE Aadi Bioscience

FAQ

When is Aadi Bioscience presenting at the TD Cowen 44th Annual Healthcare Conference?

Aadi Bioscience is presenting at the TD Cowen 44th Annual Healthcare Conference on March 4-6, 2024.

Who will be presenting the company overview at the conference?

Dave Lennon, Ph.D., President and CEO of Aadi Bioscience, will present the company overview.

Where can I watch the live webcast of the presentation?

The live webcast of the presentation will be available on the IR pages of the Aadi Bioscience website.

How long will the presentation be available for replay?

The presentation will be available for replay for approximately 30 days following each investor event.

Aadi Bioscience, Inc.

NASDAQ:AADI

AADI Rankings

AADI Latest News

AADI Stock Data

52.05M
16.00M
12.45%
52.87%
3.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PACIFIC PALISADES

About AADI

aadi bioscience inc. (aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. aadi’s lead asset, fyarrotm (sirolimus albumin-bound nanoparticles for injectable suspension), is an mtor inhibitor targeting cancers driven by genetic alterations in mtor pathway genes. supported by leading healthcare investors, aadi is currently preparing for launch of fyarro in advanced malignant pecoma, a rare type of sarcoma with no previously approved therapies. aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. a science-first mindset and entrepreneurial spirit is in our genes. aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor tsc1/2 alterations) and n